Women are two times more likely than men to die after receiving a combination of cancer immunotherapy drugs called checkpoint inhibitors, but it’s not clear if that difference is due to side effects or because the treatment isn’t working, researchers say. This new class of highly targeted drugs — which includes pembrolizumab (Keytruda), nivolumab (Opdivo)… read on > read on >







